Ovid Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Ovid Therapeutics generated cash of -$45,780,925, which is more than the previous year. Cash used in financing activities reached the amount of $30,535,201 last year. Net change in cash is therefore -$17,826,329.
Cash Flow
| 2015 | -5.48M | -56.33K | 70.63M |
|---|---|---|---|
| 2016 | -17.80M | -188.98K | -13.67K |
| 2017 | -31.46M | -47.38K | 66.70M |
| 2018 | -45.55M | -5.36M | 286.14K |
| 2019 | -51.09M | -30.04M | 86.53M |
| 2020 | -51.58M | 34.64M | 47.07M |
| 2021 | 118.61M | -1.82M | 904.08K |
| 2022 | -55.22M | -87.88M | 180.65K |
| 2023 | -45.78M | -2.58M | 30.53M |
OVID Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 46.79M | 189.72M | 72.03M | 41.89M | 36.48M | 87.12M | 51.93M | 69.94M | 4.84M |
Operating activities | |||||||||
Net income | -52.33M | -54.16M | 122.83M | -81.03M | -60.46M | -51.97M | -64.80M | -22.41M | -13.16M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 1.59M | 1.38M | 237.07K | 306.84K | 255.00K | 141.73K | 80.31K | 56.51K | 11.77K |
Stock-based compensation expense | 7.28M | 6.55M | 5.05M | 7.52M | 5.20M | 0 | 6.39M | 3.64M | 1.45M |
| Deferred income tax benefit | 7.28M | 6.55M | 5.05M | 7.52M | 5.20M | 0 | 6.39M | 3.64M | 1.45M |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 141.76K | 989.38K | -531.04K | 0 | 7.36K | 0 | -69.22K |
Inventories | 0 | 0 | -141.76K | -989.38K | 531.04K | 0 | 0 | 0 | 0 |
Accounts payable | 1.75M | -5.17M | 1.70M | 2.33M | -653.95K | 1.64M | 1.07M | 186.62K | 591.40K |
Cash generated by operating activities | -45.78M | -55.22M | 118.61M | -51.58M | -51.09M | -45.55M | -31.46M | -17.80M | -5.48M |
Investing activities | |||||||||
Purchases Of Investments | -112.44M | -172.96M | -1.63B | -9.96M | -34.79M | -50.01M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -40.30K | -1.41M | -189.40K | -390.68K | -244.04K | -352.01K | -47.38K | -188.98K | -56.33K |
Acquisitions Net | 0 | -2.5M | -1.63M | 263.44K | 186.88K | 318.14K | 0 | 0 | 0 |
Cash generated by investing activities | -2.58M | -87.88M | -1.82M | 34.64M | -30.04M | -5.36M | -47.38K | -188.98K | -56.33K |
Financing activities | |||||||||
Common Stock Issued | 535.20K | 180.65M | 925.39K | 46.73M | 86.40M | 0 | 69.75M | 0 | 70.63M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 30.53M | 180.65K | 904.08K | 47.07M | 86.53M | 286.14K | 66.70M | -13.67K | 70.63M |
Net Change In Cash | -17.82M | -142.92M | 117.69M | 30.13M | 5.40M | -50.63M | 35.18M | -18.00M | 65.09M |
Cash at end of period | 28.97M | 46.79M | 189.72M | 72.03M | 41.89M | 36.48M | 87.12M | 51.93M | 69.94M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |